

## Hepatoprotective Properties of the Salt-Like Derivatives of the Drug Xymedon with Biogenic Acids

Vyshtakalyuk A B<sup>1</sup>, Parfenov A A<sup>1</sup>, Gumarova L F<sup>1</sup>, Kondrashina D A<sup>1</sup>, Galyametdinova I V<sup>1</sup>, Semenov V E<sup>1</sup>, Nazarov N G<sup>1,2</sup>, Zobov V V<sup>1,2</sup>, Hasanshina L R<sup>2</sup>, Belyaev G P<sup>2</sup> and Diabankana R G K<sup>2</sup>

<sup>1</sup>Subdivision of the Federal State Budgetary Institution of Science "Kazan Scientific Center of Russian Academy of Sciences", Russia

<sup>2</sup>Kazan Federal University, Russia

The objective of this work was an evaluation of hepatoprotective activity of derivatives of drug Xymedon (1-( $\beta$ -oxyethyl)-4,6-dimethyl-1,2-dihydro-2-oxopyrimidon) (**I**) with biogenic acids succinic, L-ascorbic, *para*-aminobenzoic, nicotinic, L-2-amino-4-(metyltio)butane (L-methionine) (**II-VI** respectively). Formerly, we have shown that (**I**) possesses ability to stimulate liver recovery after toxic damage by CCl<sub>4</sub> [1]. New data are on derivatives (**III, IV**) that have a better specific capability if compared with (**I**) to stimulate spinal marrow recovery after trauma [2], improve body's adaptation under physical stress [3, 4], as well as demonstrate hepatoprotective properties [5-7]. We observed the most pronounced hepatoprotective properties of derivative (**III**) [6], because the compound results to minimum liver injury of steatosis and necrosis and normalize of biochemical parameters in rats with toxic hepatitis induced by CCl<sub>4</sub>. It was revealed the effect of the compound (**III**) on the antioxidative system and on the cytokines level in liver during toxic influence of CCl<sub>4</sub>. The number of pathological changed hepatocytes as fatty, balloon and hydropic dystrophy were decreased if injected with (**III**). The derivative (**III**) is more effective in comparison with other derivatives of Xymedon as well as with Xymedon, L-ascorbic acid, their mix and their co-administration and the drug Thiotriazolinum.

The research was financed by Russian Science Foundation grant number 14-50-00014.

### Biography:

Dr. Vyshtakalyuk A B is a senior researcher, Doctor of biology in the International research and innovation center of neurochemistry and pharmacology of A.E. Arbutov Institute of Organic and Physical Chemistry - Subdivision of the Federal State Budgetary Institution of Science "Kazan Scientific Center of Russian Academy of Sciences", Kazan, Russia. She graduated from Kazan State University in 1994, got PhD in Physiology of Human and Animals in 2000 and degree of Doctor in biology in 2015. She is head of the small team that studies hepatoprotective, anti-anemic and anti-inflammatory properties of new compounds. Her science interest is in the area of pharmacology, immunology, hematology and metabolism.